Drug intelligence / Profile preview

20(S)-protopanaxadiol

Development stage
Preclinical
Lead developer
Kyushu University
Modality
Small Molecules
Administration
Oral
01

Overview

20(S)-protopanaxadiol is a dammarane-type triterpenoid that serves as the aglycone (non-sugar) derivative of major ginsenosides found in plants such as Panax ginseng, Gynostemma pentaphyllum, and Aralia elata[1][7]. It is a metabolite of ginseng saponins and is formed by the deglycosylation of ginsenosides in the gut[8][9]. Preclinical studies have demonstrated that 20(S)-protopanaxadiol exhibits anticancer activity by inducing apoptosis in various tumor cells, including human endometrial cancer and colon cancer[4][5]. The anticancer effects are mediated through multiple pathways: activation of caspases (especially caspase-9), cleavage of poly(ADP-ribose) polymerase (PARP), inhibition of Akt activity, and suppression of NF-κB, JNK, and MAPK/ERK signaling[4][5]. In addition to its antitumor properties, 20(S)-protopanaxadiol has also been shown to prolong lifespan and enhance stress resistance in the model organism Caenorhabditis elegans via modulation of the insulin/IGF-1 signaling pathway[6]. As of current data, 20(S)-protopanaxadiol is not approved as a pharmaceutical drug for any indication and remains a subject of preclinical research. Its main relevance is as a bioactive natural product and a lead compound for drug discovery. **Molecular properties** - Molecular formula: C₃₀H₅₂O₃ - Molecular weight: 460.73 g/mol - Appearance: White solid - Melting point: 197–200 °C - Density: 1.036 g/cm³ - Solubility: Slightly soluble in chloroform, methanol, and pyridine[3]

Other names
(20S)-Protopanaxadiol30636-90-920(S)-APPD20(S)-Protopanaxdiol(3β,12β,20S)-dammar-24-ene-3,12,20-triolProtopanasadiolCHEMBL375563CHEMBL-375563CHEMBL 375563MFCD12032048MFCD-12032048MFCD 12032048CHEMBL280986CHEMBL-280986CHEMBL 28098620-EpiprotopanaxadiolProtopanaxadiol20S-ProtopanoxadiolProtopanaxdiol,98%ProtopanaxdiolDammar-24-ene-3,12,20-triol, (3beta,12beta)-ProtopanoxadiolProtopanaxadiol-RM
02

Targets

IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)TGFBR1EGFR (Epidermal growth factor receptor)MAP3K11 (Mitogen-activated protein kinase kinase kinase 11)YWHA (14-3-3 protein family)ESR1 (ERα)AR (Adrenergic receptors)BCL2L1 (B-cell lymphoma-extra large protein)MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on 20(S)-protopanaxadiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 20(S)-protopanaxadiol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call